with lawsuits ending Monday, VERY STRONG CHANCE of announcement for date for WK12/WK24 Data. Date WILL be in March. CEO already said it.
does anyone know if wk 12 is also at the same dosage ?
more importantly...how will it be decided that it 'works' ? 5 week results clearly showed it works. 12/24 weeks will also show the same. But AF and short sellers will say there is no placebo. So will it 'work' after their ph 2/3 ? To me it works if it is better than SOC, and so far it clearly is.
time to show the power of 2-73. He said THIS quarter....in a scientific conference.
what is the new PR firm doing
dude lets get ALZ going with great wk 12/24 results, and start of phase 2/3 asap in Q1. Why go around trying to do preclinical on many many indications ? That is not going to help them. Focus on top indication already ready for phase 3.
12:20 – 12:40 Christopher U. Missling (New York, USA)
Update on on-going phase 2a trial of new exploratory Alzheimer’s
drug ANAVEX 2-73
(supported by Anavex Life Sciences Corp.)
and remember, wk12/24 data is far more important than the previous wk5 data. It will show the sustainability of the drug.
remember, partial wk12 data in Nov for showed 78% people responded superior to SOC !!
we need to be 1/2 market cap of AXON....600m WITH strong ph 2 results.
looks like the updated info about Messling slot for 12th has been updated on SIUMED website, but not on the main AAT website yet... late breaking as usual. Will happen by tomorrow.
new money will come in next week...formal announcement for the march 12th preso will be out hopefully Monday, and with the 78% success rate they announced for partial wk12, this will be a great readout for wk12/wk24. WAY better than AXON.
Stock did not have the massive run up like it did in Nov.